Derivation of human embryonic stem cell line Genea022

Area of Science:

• Stem Cell Biology
• Reproductive Medicine
• Genetics

Background:

• Human embryonic stem cells (hESCs) are crucial for regenerative medicine and disease modeling.
• Characterization of novel hESC lines is essential for expanding research capabilities.
• The Genea022 line was derived from an ART blastocyst with commercial consent.

Purpose of the Study:

• To characterize the newly derived Genea022 human embryonic stem cell line.
• To verify its pluripotent potential and genetic stability.
• To assess its suitability for research applications.

Main Methods:

• ICM outgrowth on inactivated feeders from an ART blastocyst.
• Karyotyping (CGH) and STR analysis for genetic verification.
• Pluripotency assays including marker expression (Nanog, Oct4, Tra1-60, SSEA4), Pluritest, Alkaline Phosphatase activity, and teratoma formation.
• Mycoplasma and contamination testing.

Main Results:

• Genea022 demonstrated typical pluripotent cell morphology and a 46, XY karyotype.
• High expression of pluripotency markers (Nanog, Oct4, Tra1-60, SSEA4) and a Pluritest score of 42.95.
• Successful tri-lineage teratoma formation confirmed pluripotency; the line was free of Mycoplasma and contamination.

Conclusions:

• The Genea022 hESC line is a genetically verified, pluripotent, and safe resource for research.
• Its characteristics support its use in studies requiring male human pluripotent stem cells.
• This cell line expands the available tools for stem cell research and therapeutic development.